Efmody

Efmody is a medicine used to treat an inherited condition called congenital adrenal hyperplasia (CAH) in patients 12 years old and above. CAH is rare, and Efmody was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 27 July 2005. Further information on the orphan designation can be found [here](/en/medicines/human/orphan-designations/eu-3-05-296). Efmody contains the active substance hydrocortisone and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but Efmody has a different use and is available in different strengths as capsules formulated to release the active substance over a prolonged period. The reference medicine for Efmody capsules is Hydrocortone tablets.